Andy Tu
Immunitas Therapeutics (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Virus-based gene therapy research, Hematopoietic Stem Cell Transplantation, Immune Cell Function and Interaction, Genomics and Chromatin Dynamics
Most-Cited Works
- → Dual Binding of Chromomethylase Domains to H3K9me2-Containing Nucleosomes Directs DNA Methylation in Plants(2012)565 cited
- → DDR complex facilitates global association of RNA polymerase V to promoters and evolutionarily young transposons(2012)227 cited
- → Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy(2013)61 cited
- → Analysis of the Effect of COVID-19 on the Stock Market and Investing Strategies(2020)59 cited
- → Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy(2017)32 cited
- → Discriminating between Interstitial and Circulating Leukocytes in Tissues of the Murine Oral Mucosa Avoiding Nasal-Associated Lymphoid Tissue Contamination(2017)15 cited
- → Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies(2013)3 cited
- → Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications(2014)1 cited
- → Second-Generation Chimeric Antigen Receptors Successfully Modify Hematopoietic Stem Cells for Immunotherapy of B-Lineage Malignancies(2014)1 cited
- → 1332 Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D(2022)1 cited